Welcome

Executive Director Jean Georges, June 2024Alzheimer Europe's April 2025 newsletter brings you the latest news on developments in the dementia field, across Europe and beyond.

Summaries of a few of our top stories appear below.

Our monthly newsletter reaches almost 11,000 people, who have an interest in dementia, from across Europe and beyond.

We are always happy to receive feedback, or suggestions regarding news items to share.

 
14 April: Alzheimer Europe welcomes two new colleagues

A warm welcome to two new arrivals who joined the Alzheimer Europe team in April: Isabelle Collot, who is our new Conference Coordinator and Margarita Reyes, who joins the team as a Communications Officer. We are all delighted to be working with them both!
15 April: The European Commission has authorised lecanemab for treatment of early Alzheimer’s disease

EU Commission building and EU flagsThe European Commission has granted EU authorisation for lecanemab to treat mild cognitive impairment (MCI) in the early stages of Alzheimer’s disease. This authorisation comes under strict conditions, with the drug being for use in people who have only one or no copy of the ApoE4 gene and who have amyloid beta plaques in the brain. 
30 April: Record number of abstracts submitted for this year's Alzheimer Europe Conference!

35AEC Bologna teaser image squareAlzheimer Europe, Alzheimer Uniti Italia and Federazione Alzheimer Italia would like to thank everyone who submitted abstracts for the 35th Alzheimer Europe Conference (#35AEC), taking place from 6-8 October 2025, in Bologna (Italy). A record number of 926 abstracts was received this year, which will be reviewed by our Scientific Committee during May.